Enbloc cell short deck 210210

Target protein production can be 385,000,000 μg from 1 kg of insect eggs = 5 μg × 2 times = 38,500,000 dose.
Expression System ExpiCHO Expi293 FreeStyle CHO insect eggs
Cost of transfection $2,174 / L $1,735 / L $1,201 / L $700 / kg
Protein yields 1.5 g / L 1 g / L 0.05 g / L 385 g / kg
Total cost for 0.1g of protein $146 $174 $2,403 $0.18

enbloc cell™
platform
Biopharmaceutical
companies
Customers
(Hospital, Government)
Biotech Startups
CMOs
(cell culture platform)
Supply
enbloc cell™
Supply enbloc cell™
Supply raw materials
deliver finished
product
mass production order
Mass production
order
Out-licensing
of new
medicines
Supply raw
materials

19.0
33.1
US$0
US$5
US$10
US$15
US$20
US$25
US$30
US$35
FY2020 FY2025
MarketsandMarkets Research, November 2020
Global Cell culture market
Key manufacturers for cell culture
media

Date Profile
13 Dec 2013 Estabilished of enbloc cell LLC
11 Dec 2014 Patent Technology Award from the Korean Intellectual Property Office
01 Jul 2018 Converted an LLC to a Corporation

Platforms RNA
Viral vector
Protein subunit Virus (inactive)
single dual
Manufacturer
(name)
Moderna
(BNT162b2)
Pfizer
(mRNA-1273)
AstraZeneca
(AZD1222)
Russia
(Sputnik V) Novavax
(NVX-CoV2373)
China Sinovac
(CoronaVac)
China Sinopharm
(BBIBP-CorV)
1st & 2nd rAd5 1st rAd26 / 2nd rAd5
Expiration date
6 months at -20℃
30 days at 2~8℃
6 months at -70℃
5 days at 2~8℃
6 months at 2~8℃
Freeze-dried at
2~8℃
2~3 years at
2~8℃
1 year at 2~8℃
Methods Day 0 and 21 Day 0 and 21 Day 0 and 28 Day 0 and 21 Day 0 and 21 1 time
Phase 3 trial 94.5% 95% 62~90% 91.6% 89.3% 50.38% 79.34%
Beyond 2022? X X X O → ? O X O

Rooftop: vertical farm for adjuvant production
(tissue culture of Quillaja saponaria)
ground floor: insect
factory, biotech lab
facility, and office

Sales by enbloc cell
(Korean peninsula only)
Foreign Biopharma companies
(non-exclusive contract based)

Chicken egg as living biofactories Stainless steel stirred-tank bioreactor
[application] produce of live attenuated vaccine and inactivated
vaccine
[application] produce of recombinant vaccine and therapeutic
proteins (antibody, enzyme etc)
[advantages] low cost, high productivity and production yield
rate (compared to cell culture)
[advantages] high immunogenicity, minimize side effects,
production period shortening (about 3 months)
[disadvantages] low immunogenicity, high side effects,
production period is relatively long (about 6 months)
[disadvantages] inefficiency, technical complexity and limited
scalability / high cost, low productivity and production yield
rate

Company name Algenex S.L. in Spain Sysmex Corp. in Japan
Technology Trichoplusia ni pupae Bombyx mori larvae and pupae

Inoculation and purification process of existing 'bioreactor using live insects'
- Directly injected into a body of larva or pupa by a syringe (handwork or semi-auto)
- Thick cocoon covered in the pupa should also be removed manually
- Whole larva or pupa produced proteins require more extensive purification
(because there is feed or gut microbiome)
Not suitable for industrial mass production

Ephestia kuehniella eggs
egg collection device
After removing the chorionic layer and wax layer from
eggshell by using non-toxic chemicals substances or
compositions, inoculation by spraying or soaking
recombinant baculovirus into pyralid moths egg
In the insect industry, large quantities of pyralid
moths egg (which are insect pests of stored foods)
are being mass produced for the purpose of
producing commercial natural enemies
Can almost completely automate the
production process of recombinant protein

rearing container rearing room

egg collection room
emerge bag

DEC 2003 JAN 2004 FEB 2004 MAR 2004 APR 2004 MAY2004 JUN 2004 JUL 2004 AUG 2004 SEP 2004 OCT 2004 NOV 2004 DEC 2004
rice bran (KRW) 13.75 16.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00 10.00
maize flour (KRW) 8.94 78.40 78.40 78.40 78.40 78.40 83.40 83.40 83.40 83.40 83.40 83.40
wheat flour (KRW) 9.04 32.00
glycerine (KRW) 137.76 105.00 105.00 105.00 105.00 105.00 105.00 105.00 105.00 105.00 105.00 105.00 105.00
vitamin powder (KRW) 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00
Subtotal (KRW) 174.49 158.00 198.40 198.40 198.40 198.40 198.40 203.40 203.40 203.40 203.40 203.40 203.40
monthly input rearing containers (pcs) 1435 1809 2797 3720 3960 3120 3120 3240 2880 3120 3240 3120 3120
monthly raw material cost (KRW) 250,393 285,822 554,925 738,048 785,664 619,008 619,008 659,016 585,792 634,608 659,016 634,608 634,608
daily workers (person) 1.5 1.5 2.0 1.5 1.75 2.0 2.0 2.0 1.5 1.5 1.5 2.0 2.0
Salaries of Manager (KRW) 1,000,000 566,667 566,667 566,667 566,667 566,667 566,667 566,667 566,667 566,667 566,667 466,667 466,667
monthly labor cost (KRW) 2,200,000 1,766,667 2,166,667 1,766,667 1,966,667 2,166,667 2,166,667 2,166,667 1,766,667 1,766,667 1,766,667 2,066,667 2,066,667
2,450,393 2,052,489 2,721,591 2,504,715 2,752,331 2,785,675 2,785,675 2,825,683 2,352,459 2,401,275 2,425,683 2,701,275 2,701,275
monthly amount of harvest (g) 849.58 1248.20 639.64 2064.98 2894.33 3600.14 3791.19 4058.21 4007.49 4296.45 3633.36 4318.30 3926.41
monthly amount of seedling (g) 86.10 108.54 137.42 173.60 184.80 145.60 145.60 151.20 134.40 145.60 151.20 145.60 145.60
rate of seeding (%) 10.1% 8.7% 21.5% 8.4% 6.4% 4.0% 3.8% 3.7% 3.4% 3.4% 4.2% 3.4% 3.7%
monthly amount of production (g) 763.48 1139.66 502.22 1891.38 2709.53 3454.54 3645.59 3907.01 3873.09 4150.85 3482.16 4172.70 3780.81
3,209.51 1,800.97 5,419.12 1,324.28 1,015.80 806.38 764.12 723.23 607.39 578.50 696.60 647.37 714.47
2,928.38 1,643.22 4,944.45 1,208.28 926.82 735.75 697.19 659.89 554.18 527.83 635.59 590.66 651.89
Manufacturing cost per 1g eggs (KRW)
Production of Cadra cautella eggs
Cost of raw material
per rearing
container
Raw material cost
Labor cost
Production amount
Manufacturing cost per 1kg eggs (USD)
Manufacturing cost total
On March 2005, Expansion of production facilities (gross area 70.4 ㎡, monthly input rearing containers 7,563 pcs)

1. 줄알락명나방
구분
수확
유충 제품 판매
소계
Seed 사용
쌀좀알벌
으뜸애꽃노린재
알 제품 판매
소계
2. 쌀좀알벌
구분
g 35.31
박스 141.2
g 39.50
박스 158
g 0.25
박스 1
g -2.77
박스 -11.1
g 72.29
박스 289.2
3. 으뜸애꽃노린재
구분
수확
약충 제품 판매
소계
Seed 사용
제품 판매
내부출고(교육/시범포)
재고 평가량
소계
46.30
박
스
91.4 185.2
박
스
g 22.86
폐기량
Seed 사용
제품 판매
내부출고
(교육/시범포)
소계
g
3024
31.18 110.27
박
스
124.7 441.1
1012.00
출고
0
682
재고량
1368
281
수량
3024
0
414.97
5162.59
200.00
6798.91
폐기량
42
0.00
출고
수량
424.32
폐기량
수량
재고량
출고
수확 56 0 40
재고 평가량
7563
머미 제품
(73,000마리/g)
(18,000마리/박스)
제품구분 생산량
전월재고
유충 (30만 마리/통) 12 84
g
생산월보
2005년 4월
기주구분 생산량
전월재고
g 133.20
재고량
알
(50,000개/g)
7080.68
7182
0
7182
유충
(2,000마리/통)
통 6504 6843
제품구분 생산량
약충
(600마리/통)
(1,000마리/통)
2190
전월재고
통 2202
병 0
성충 제품
(600마리/병)
1890
927
276
613
2
36
담당 계장 팀장 부서장 연구소장
결
재

On 2013, non-exclusive commercial license agreement On 2019, non-exclusive commercial license agreement

(Unit: thousand KRW)
Description FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019 FY2020
Assets
Current assets 8,961 9,893 166,285 43,715 49,717 36,089 37,191 33,932
Quick assets 8,961 9,893 166,285 12,501 18,625 5,067 6,170 2,911
Inventories 0 0 0 31,215 31,091 31,021 31,021 31,021
Non-current assets 2,200 54,724 114,590 521,200 789,211 636,082 483,667 346,662
Tool, Apparatus, Fixtures 0 26,474 33,392 8,606 8,848 4,437 1,958 865
Industrial property rights 0 11,387 35,093 366,003 584,872 490,078 394,013 299,600
Total assets 11,161 64,617 280,875 564,916 838,927 672,171 520,858 380,594
Liabilities
Current liabilities 8,382 164,142 214,685 108,174 172,573 186,399 370,391 404,305
Suspense received 0 61,000 106,900 0 12,978 63,890 364,994 395,605
Short-term borrowings 0 100,000 100,000 100,000 118,000 118,000 0 0
Non-current liabilities 0 0 160,000 160,000 160,000 160,000 0 0
Long-term borrowings 0 0 160,000 160,000 160,000 160,000 0 0
Total liabilities 8,382 164,142 374,685 268,174 332,573 346,399 370,391 404,305
Capital
Capital of ordinary shares 10,000 10,000 10,000 580,000 1,000,000 439,058 439,058 439,058
Capital reserve 0 0 0 0 0 0 0 0
Retained earnings (accumulated deficit) -7,222 -109,525 -103,810 -283,259 -493,646 -113,286 -288,591 -462,769
Total equity 2,778 -99,525 -93,810 296,741 506,354 325,772 150,467 -23,711
Total liabilities and equity 11,161 64,617 280,875 564,916 838,927 672,171 520,858 380,594

Sales 0 0 0 8,182 9,605 864 17,233 0
Cost of sales 0 0 0 4,835 124 70 0 0
Gross profit (loss) 0 0 0 3,347 9,482 794 17,233 0
Selling and administative expenses 7,222 129,003 173,195 218,399 227,013 222,839 192,648 176,109
Salaries 1,331 19,382 13,134 4,588 4,733 27,497 1,571 3,023
Depreciation expenses 0 0 0 24,302 5,694 3,727 2,479 1,093
Ordinary research and development expenses 0 0 50,533 90,987 28,090 7,908 3,926 3,023
Amortization of intangible asset 0 0 0 46,282 114,414 149,417 149,366 135,319
Operating profit (loss) -7,222 -129,003 -173,195 -215,053 -217,531 -222,045 -175,415 -176,109
Non-operating income 1 30,913 191,401 49,883 16,670 42,934 118 2,138
Government subsidy 0 30,267 191,187 49,800 16,500 5,649 7 1,000
Royalty income 0 0 0 0 0 37,210 0 0
Non-operating expenses 0 4,213 12,492 14,279 9,526 1,472 8 207
Interest expenses 0 2,713 8,892 11,446 7,717 0 0 0
Donations 0 1,500 3,600 1,500 0 0 0 0
Loss on disposal of tangible assets 0 0 0 396 1,303 955 0 0
Net income (loss) before income tax expenses -7,222 -102,303 5,715 -179,449 -210,387 -180,582 -175,305 -174,178
Income tax expenses 0 0 0 0 0 0 0 0
Net income (loss) -7,222 -102,303 5,715 -179,449 -210,387 -180,582 -175,305 -174,178

I. Unappropriated deficit 7,222 109,525 103,810 283,259 493,646 113,286 288,591 462,769
1. Unappropriated deficit at the beginning of a period 0 7,222 109,525 103,810 283,259 493,646 113,286 288,591
2. Cumulative effect of accounting change 0 0 0 0 0 0 0 0
3. Gain on prior period error corrections 0 0 0 0 0 0 0 0
4. Loss on prior period error corrections 0 0 0 0 0 0 0 0
5. An interim dividend 0 0 0 0 0 0 0 0
6. Surplus from retirement of capital stock 0 0 0 0 0 -560,942 0 0
7. Net loss during the term 7,222 102,303 -5,715 179,449 210,387 180,582 175,305 174,178
II. Deficits disposal amount 0 0 0 0 0 0 0 0
1. Importation amount of other surplus reserve 0 0 0 0 0 0 0 0
2. Importation amount of other legal reserve 0 0 0 0 0 0 0 0
3. Importation amount of earned surplus reserve 0 0 0 0 0 0 0 0
4. Importation amount of revaluated reserve 0 0 0 0 0 0 0 0
5. Importation amount of capital reserve 0 0 0 0 0 0 0 0
III. Unappropriated deficit to be carried forward 7,222 109,525 103,810 283,259 493,646 113,286 288,591 462,769

Patent Technology Award from the Korean Intellectual Property Office

Enbloc cell short deck 210210

Recommended

Recommended

More Related Content

Similar to Enbloc cell short deck 210210

Similar to Enbloc cell short deck 210210 (20)

Recently uploaded

Recently uploaded (20)

Enbloc cell short deck 210210